会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
    • 使用甲磺酸伊马替尼治疗费城阳性白血病的方法
    • US08697702B2
    • 2014-04-15
    • US13129903
    • 2009-11-30
    • Yanfeng WangThea KalebicTimothy P HughesDeborah White
    • Yanfeng WangThea KalebicTimothy P HughesDeborah White
    • A61K31/497
    • A61K31/506
    • The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Phi+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of (a) administering a predetermined fixed amount of Imatinib as a free base or in the form of a pharmaceutically acceptable salt thereof to the human patient, (b) collecting at least one blood sample from the patient, e.g. within the first 12 months of treatment, (c) determining the plasma trough level (Cmin) of Imatinib, (d) determining the OCT-1 Activity in the blood sample, and (e) adjusting the dose of Imatinib applied to the individual patient in a manner that an Imatinib Cmin value is achieved in the patient of at least 800 ng/mL, if in step (c) an Imatinib Cmin value of less than 800 ng/mL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng/200,000 cells.
    • 本发明涉及在人类患者群体中治疗特定慢性骨髓性白血病(CML)中的费城阳性白血病(Ph +白血病)的方法。 更具体地,本发明涉及在患有Ph +白血病的人类患者中治疗Ph +白血病(例如CML或Phi + ALL)的方法,包括以下步骤:(a)施用预定的固定量的伊马替尼作为游离碱或 其药学上可接受的盐的形式提供给人类患者,(b)从患者收集至少一种血液样品, 在治疗的头12个月内,(c)确定伊马替尼的血浆谷值(Cmin),(d)确定血液样品中的OCT-1活性,和(e)调整施用于个体患者的伊马替尼剂量 如果在步骤(c)中发现伊马替尼Cmin值小于800ng / mL,并且在步骤(d)中OCT-1 活性发现低于6.0至10.0ng / 20万个细胞。
    • 9. 发明申请
    • MULTI-TOUCH POSITIONING METHOD AND MULTI-TOUCH SCREEN
    • 多触点定位方法和多触摸屏
    • US20100090986A1
    • 2010-04-15
    • US12578717
    • 2009-10-14
    • Yanfeng WANG
    • Yanfeng WANG
    • G06F3/042
    • G06F3/0421G06F3/0428G06F2203/04808
    • The present invention relates to a multi-touch positioning method and a multi-touch screen. The multi-touch positioning method comprising: emitting, by a first infrared ray generator set at a first angle of a display panel, infrared rays at a first wavelength; emitting, by a second infrared ray generator set at a second angle, infrared rays at a second wavelength; receiving the infrared rays of the first wavelength and generating a first infrared ray image by a first infrared ray image sensor set at an opposite angle of the first angle; receiving the infrared rays of the second wavelength and generating a second infrared ray image by a second infrared ray image sensor set at an opposite angle of the second angle; and performing processings for the first infrared ray image and the second infrared ray image to determine at least one touch point.
    • 本发明涉及多点触摸定位方法和多点触摸屏。 所述多点触摸定位方法包括:通过由显示面板的第一角度设置的第一红外线发生器发射第一波长的红外线; 通过以第二角度设置的第二红外线发生器发射第二波长的红外线; 接收第一波长的红外线并通过设置在与第一角度相反的角度的第一红外线图像传感器产生第一红外线图像; 接收第二波长的红外线,并且以与第二角度相反的角度设置的第二红外线图像传感器产生第二红外线图像; 以及对所述第一红外线图像和所述第二红外线图像执行处理以确定至少一个触摸点。
    • 10. 发明申请
    • METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS
    • 用ABL酪氨酸激酶抑制剂优化治疗菲律宾阳性白血病的方法
    • US20090281113A1
    • 2009-11-12
    • US12442126
    • 2007-09-20
    • Insa GathmannFrancois-Xavier MahonMathieu MolimardStephane PicardYanfeng Wang
    • Insa GathmannFrancois-Xavier MahonMathieu MolimardStephane PicardYanfeng Wang
    • A61K31/506A61P35/02
    • A61K31/506A61K31/00G01N33/49G01N2800/52
    • The present invention provides a method of treating Philadelphia positive (Ph+) leukemia, such as Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML), in a human patient population comprising the steps of (a) administering a predetermined fixed amount of a Bcr-Abl tyrosine kinase inhibitor, such as Imatinib, or a pharmaceutically acceptable salt thereof to human patients suffering from a Ph+ leukemia, (b) collecting at least one blood sample from said patients, (c) determining the plasma trough level (Cmin) of the Bcr-Abl tyrosine kinase inhibitor or of a metabolite thereof as well as the MMR rates, (d) assessing a discrimination potential of trough plasma concentrations for MMR and identifying a Cmin threshold for optimal sensitivity and specificity and (e) adjusting the dose of the inhibitor of the Bcr-Abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient population and, optionally, future patients suffering from a Ph+ leukemia in a manner that a Cmin is achieved in each single patient equal to or higher than the Cmin threshold obtained under step (d).
    • 本发明提供了一种在人类患者群体中治疗费城阳性(Ph +)白血病如费城染色体阳性急性淋巴细胞白血病(Ph + ALL)或慢性骨髓性白血病(CML)的方法,包括以下步骤:(a) 将固定量的Bcr-Abl酪氨酸激酶抑制剂(例如伊马替尼)或其药学上可接受的盐给予患有Ph +白血病的人类患者,(b)从所述患者收集至少一种血液样品,(c)测定血浆槽 Bcr-Abl酪氨酸激酶抑制剂或其代谢物的水平(Cmin)以及MMR率,(d)评估MMR的谷浆浓度的鉴别潜力,并鉴定最佳灵敏度和特异性的Cmin阈值,(e )调节从所述患者群体应用于个体患者的Bcr-Abl酪氨酸激酶抑制剂或其药学上可接受的盐的剂量 以及任选地,患有Ph +白血病的未来患者以等于或高于步骤(d)获得的Cmin阈值的每个单个患者中实现Cmin的方式。